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Cardiovascular risk factors in pre-dialysis patients: Baseline chronic kidney disease [1]. Even at the onset of dialysis,
data from the Chronic Renal Impairment in Birmingham about one third of patients have clinical manifestations
(CRIB) study. of congestive heart failure, one quarter have angina, andBackground. Patients with end-stage kidney failure have a
about 10% have a history of myocardial infarction [2].greatly increased risk of developing premature cardiac and
These observations suggest that such conditions becomevascular disease. However, little is known about the evolution
of cardiovascular diseases in individuals with less severely im- established early in the course of chronic kidney failure.
paired kidney function. The Chronic Renal Impairment in Birmingham (CRIB)
Methods. The prevalence of cardiovascular diseases and of study set out to investigate the relationship between kid-suspected cardiovascular risk factors was studied in a group of
ney function and cardiovascular risk factors in a cohort369 individuals (median age, 63 years, 67% male) with various
of patients with chronic kidney failure not requiring renaldegrees of impaired kidney function (calculated creatinine
clearances 6 to 105 mL/min), in 103 patients with angiographi- replacement therapy (CKD group). For comparison pur-
cally proven coronary artery disease, and in 103 apparently poses, two control groups, unselected for renal function,
healthy individuals. These patients are being followed prospec-
were also studied; one comprised overtly healthy individ-tively.
uals with minor medical complaints (HI group), and theResults. Of those patients with kidney disease, 34% had a
history of vascular disease and 21% had left ventricular hyper- other, patients with angiographically-proven coronary
trophy on electrocardiogram at baseline. Traditional risk fac- artery disease (CAD group) [3].
tors were prevalent, with a history of hypertension in 76% of
kidney disease patients, diabetes in 15%, and dyslipidemia with
reduced low-density lipoprotein (LDL) cholesterol, elevated METHODS
serum triglycerides, and decreased high-density lipoprotein
Chronic kidney disease patients with a serum creati-(HDL) levels. Other possible cardiovascular risk factors include
elevated concentrations of plasma homocysteine, as well as nine greater than 1.47 mg/dL (130 mol/L) and the two
low serum albumin and hemoglobin levels. Patients with more age- and sex-matched control groups were recruited [3].
severely impaired renal function had lower diastolic blood pres- Medical history, medications, height, weight, and blood
sures, lower LDL and HDL cholesterol levels, were more ane-
pressure were documented, venous blood samples weremic, and had higher plasma homocysteine concentrations.
collected, a 12-lead electrocardiogram was recorded, andConclusions. Vascular disease and left ventricular hypertro-
phy are prevalent among patients with chronic kidney disease evidence of left ventricular hypertrophy (LVH) sought
not requiring dialysis. In addition to traditional risk factors, using the Sokolow-Lyon criteria. Total cholesterol and
other features of the uremic syndrome such as anemia, hyper- triglyceride were assessed using standard techniques, high-
homocysteinemia, and inflammation (suggested by hypoalbum-
density lipoprotein was measured directly, and low-den-inemia) may contribute.
sity lipoprotein calculated using the Friedewald equation.
Plasma homocysteine was analyzed by reverse-phase
high performance liquid chromatography with coulomet-With the widespread availability of renal replacement
ric detection. Discrete and continuous variables weretherapies, cardiovascular disease has emerged as the
compared using Chi-squared and unpaired t tests, respec-leading cause of premature death among individuals with
tively. Relationships between correlated parameters
were assessed using regression methods. Differences and
trends in variables with respect to level of kidney func-Key words: anemia, cardiovascular disease, chronic kidney disease,
hyperhomocysteinemia, inflammation, left ventricular hypertrophy. tion were assessed by analysis of variance and rank corre-
lation among quintiles of serum creatinine. 2003 by the International Society of Nephrology
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Fig. 1. Homocysteine concentrations (mean  95% CI) in healthy
Fig. 2. Hemoglobin concentrations (mean  95% CI) in healthy con-controls, coronary artery disease (CAD), and chronic kidney disease
trols, coronary artery disease (CAD) patients and chronic kidney dis-(CKD) patients. Concentrations are stratified by quintile of serum
ease (CKD) patients stratified by quintile of serum creatinine.creatinine (median Q1  1.92 mg/dL, Q2  2.31 mg/dL, Q3  2.98
mg/dL, Q4  3.79 mg/dL, and Q5  6.32 mg/dL).
LDL cholesterol (P 0.001), and lower HDL cholesterol
RESULTS (P  0.01), but no difference in triglyceride concentra-
tions (P  0.22).Of the CKD group, 34% had vascular disease and,
In addition to these traditional risk factors, we investi-while the prevalence increased with age, the proportion
gated the prevalence of other metabolic abnormalitieswas similar across all five quintiles of kidney function.
implicated in the pathogenesis of cardiovascular diseaseLeft ventricular hypertrophy was identified on electro-
in the context of chronic kidney failure. Plasma homocys-cardiogram in 21% of these patients as compared to 9%
teine levels were higher in CKD (mean 20.6 mol/L) asin the CAD group (P  0.01) and 4% in the HI group
compared to the CAD (12.3 mol/L; P  0.001) and HI(P  0.001), with a higher prevalence among those indi-
viduals with more advanced renal impairment (test for (10.0 mol/L; P  0.001) groups. Patients with more
trend P  0.01). Among the CKD patients, prevalent severe kidney impairment had higher plasma homocys-
traditional risk factors included diabetes mellitus in 15% teine levels (test for trend P  0.001; Fig. 1), despite
(CAD 10%, PNS, HI 6%, P 0.05) and hypertension more frequent use of folic acid and vitamin B prepara-
in 76% (CAD 49%, P  NS, HI 30%, P  0.001). A tions among the highest quintile of serum creatinine
similar proportion of patients in all three groups were (22% vs. 10% in the other 4 quintiles; P  0.01). Hemo-
past or present smokers (CKD 61%, CAD 70%, HI globin concentrations were lower among patients with
56%). Body mass index was lower in the patients with kidney disease as expected (12.1 g/dL vs. 14.0 g/dL in
kidney disease than in the CAD group (P  0.05), and CAD group and 13.8 g/dL in HI, both P  0.001). Al-
76% of the CKD patients were hypertensive compared though the use of erythropoietin and iron were higher
with 49% in the CAD group (P  NS) and 30% of in the quintile with the most severe renal impairment,
overtly healthy individuals (P  0.001). While systolic advanced renal failure was associated with a lower hemo-
pressure was similar at all levels of kidney function, dia- globin (test for trend P  0.001; Fig. 2). In the CKD
stolic pressure was lower in CKD patients with more group, LVH was associated with more severe anemia,
severe renal impairment (test for trend P  0.001) and as well as a higher systolic blood pressure (Fig. 3). Finally,
was associated with a wider pulse pressure (test for trend serum albumin concentrations were lower in patients
P  0.05). These results are likely to be confounded by with renal impairment (41.8 g/dL vs. 43.6 g/dL in CAD
the use of antihypertensive medications since a larger group and 44.1 g/dL in HI group, both P 0.001), partic-
number of drugs were prescribed to patients with more ularly in those with more severe renal impairment (test
advanced kidney failure (test for trend P  0.001). In for trend P  0.001).
contrast, lipid-lowering therapies were prescribed equally
across the quintiles of kidney function (mean 18%, test
DISCUSSIONfor trend P  0.37), and are unlikely to explain trends
These results confirm the high prevalence of cardio-in dyslipidemia. Patients with kidney disease had lower
vascular diseases in patients with chronic kidney diseaseLDL cholesterol levels than the HC group (130 mg/dL
not requiring renal replacement therapy, and emphasizevs. 140 mg/dL; P 0.01), lower levels of HDL cholesterol
the potential for early therapeutic intervention to reduce(46 mg/dL vs. 53 mg/dL; P 0.001), and higher triglycer-
morbidity and mortality in these individuals. Our find-ide concentrations (179 mg/dL vs. 113 mg/dL; P 0.001).
ings are in keeping with other studies of cardiac andIncreasing severity of kidney failure was associated with
lower total cholesterol (test for trend P  0.001), lower vascular disease among similar populations, even when
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general population [8], and in patients with chronic kid-
ney disease on dialysis [9].
Although none of these risk factors have been proven
to contribute to cardiovascular disease in patients with
renal impairment, prospective follow-up of the CRIB
cohort will help to identify those factors with a substan-
tial impact on the development of cardiovascular events,
although much larger studies will be required to identify
more moderate associations. However, this cross-sec-
tional analysis does demonstrate that, even in patients
with relatively mild renal impairment, there is a substan-
tial burden of cardiovascular disease along with changes
in a number of traditional and putative cardiovascular
risk factors. Since even minor degrees of renal impair-
ment are associated with increased relative risk of cardio-
vascular disease and are relatively common [10], theseFig. 3. Prevalence of left ventricular hypertrophy on electrocardio-
gram by Sokolow-Lyon criteria stratified by hemoglobin and systolic observations raise the possibility that mechanisms re-
blood pressure. sponsible for the pathogenesis of aggressive cardiovascu-
lar disease in dialysis patients may be relevant to a much
broader population.
LVH has been assessed by echocardiogram [2, 4]. While
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